Abstract
- Time until ejaculation during sexual intercourse is highly variable. Some men and their partners find sex unsatisfactory because they feel ejaculation occurs too quickly. Psycho-behavioural therapy is the first option.
- Dapoxetine, a short-acting serotonin reuptake inhibitor, is the first drug to be authorised for use in premature ejaculation in some EU member states.
- Four double-blind randomised placebo-controlled trials in a total of 4414 men are available. At best, only one in three men and one in five women perceived at least a moderate improvement in sexual satisfaction through a specific effect of dapoxetine. A substantial placebo effect was observed in one-third of participants of both sexes.
- Dapoxetine exposes men to the numerous adverse effects of all serotonin reuptake inhibitors, some of which can be severe, such as self-harm, aggressive behaviour, and serotonin syndrome. Postural hypotension and syncope can also occur.
- Dapoxetine is strongly metabolised by the cytochrome P450 isoenzymes CYP 3A4 and CYP 2D6, and thus carries a risk of numerous pharmaco-kinetic interactions.
- In practice, there is no justification for exposing men to potentially serious adverse effects for only a moderate symptomatic improvement in a poorly defined disorder. Behavioural approaches should remain the cornerstone of therapy.
©Prescrire March 2010
"Dapoxetine. Premature ejaculation: not worth the risk" Prescrire International 2010; 19 (105 ): 12-14 (pdf, subscribers only)